A new systematic review published in the journal Cureus finds that psychedelic-assisted therapies such as ketamine, esketamine, and psilocybin may offer fast-acting and sustained relief for those with treatment-resistant depression (TRD), while also improving real-world functioning.
Ketamine (left) and psilocybin mushrooms (right).
The review analyzed 10 randomized controlled trials published within the past year, all of which assessed various psychedelic agents in adults with TRD. Most trials reported significant reductions in depressive symptoms, with esketamine and high-dose psilocybin showing effects that lasted for months. Several studies also found that these therapies improved daily functioning and workplace productivity. Notably, esketamine nasal spray was shown to outperform quetiapine in both symptom remission and productivity metrics over a 32-week period.
The safety profile of these substances was favorable, with few adverse cognitive effects. Trials involving ketamine and esketamine—both in oral and intravenous forms—showed no meaningful cognitive decline, and psilocybin’s benefits were strongly tied to the intensity of the psychedelic experience, suggesting both neurochemical and psychological mechanisms of action.
The findings highlight a growing body of evidence supporting psychedelic-assisted therapies as viable alternatives or adjuncts for patients unresponsive to conventional antidepressants. With rapid onset and real-world benefits, researchers say these treatments represent a potential paradigm shift in managing chronic depression.
Future studies are needed to further assess long-term outcomes, standardize dosing, and broaden research across diverse populations.
